Zealand Pharma A/S/ADR
ZLDPF$3.26B
Mid CapNASDAQBiotechnology🇺🇸North AmericaSOBORG
Drugs in Pipeline
4
Phase 3 Programs
3
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
ZLDPF News
Catalyst Timeline
0 upcoming, 1 past
No catalysts found.
Drug Pipeline
dasiglucagon
Congenital Hyperinsulinism
Glepaglutide
Short Bowel Syndrome
GlucaGen
Hypoglycemia
Petrelintide
Overweight
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
dasiglucagon | Phase 3 | Congenital Hyperinsulinism | - | - |
Glepaglutide | Phase 3 | Short Bowel Syndrome | - | - |
GlucaGen | Phase 3 | Hypoglycemia | - | - |
Petrelintide | Phase 2 | Overweight | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply